Serum prostate specific antigen (PSA) level and digital rectal examination (DRE) constitute the major screening tests for PCa diagnosis, while the transrectal ultrasound-guided prostate biopsy (PBs) provides the final confirmation of cancer presence [6]. The gene discussed is KLK3; the disease is posterior cortical atrophy.